The endless story of markers of renal function and cardiovascular risk

Luis M Ruilope^{1

2

3

4}, Elena Rodríguez-Sánchez¹, Gema Ruiz-Hurtado^{1

2}

Affiliations

¹ Cardiorenal Translational Laboratory & Hypertension Unit, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
² CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.
³ Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ and CIBERESP, Madrid, Spain.
⁴ Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.

Editorial

Luis M Ruilope et al. Eur Heart J. 2019.

. 2019 Nov 1;40(42):3494-3495.

doi: 10.1093/eurheartj/ehz489.

Luis M Ruilope^{1

2

3

4}, Elena Rodríguez-Sánchez¹, Gema Ruiz-Hurtado^{1

2}

¹ Cardiorenal Translational Laboratory & Hypertension Unit, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
² CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.
³ Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ and CIBERESP, Madrid, Spain.
⁴ Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.

No abstract available

Comment on

Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial.
Garimella PS, Lee AK, Ambrosius WT, Bhatt U, Cheung AK, Chonchol M, Craven T, Hawfield AT, Jotwani V, Killeen A, Punzi H, Sarnak MJ, Wall BM, Ix JH, Shlipak MG. Garimella PS, et al. Eur Heart J. 2019 Nov 1;40(42):3486-3493. doi: 10.1093/eurheartj/ehz392. Eur Heart J. 2019. PMID: 31257404 Free PMC article. Clinical Trial.